Covance's Clinical Pharmacology Business Receives Lilly's Global Supplier
Award for the Second Consecutive Year
PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD)
today announced that its clinical pharmacology business received Lilly's 2009
Global Supplier Award for its commitment to helping Lilly meet its corporate
objectives. This was the second consecutive year Covance was recognized for
outstanding customer service for its clinical pharmacology services. The Lilly
Global Supplier Award acknowledges those key suppliers who contribute the best
in innovation and technology towards Lilly's success.
Covance was judged by a committee of Lilly representatives on criteria
including delivery of exemplary quality, service, speed, total cost reduction,
supplier relationship management, and supplier diversity.
"It's a true honor to be one of the dozen companies to win this award
among Lilly's 6,500 global suppliers," said Covance Chief Operating Officer
Wendel Barr. "Delivering exceptional customer service is always a first
priority for Covance, and being recognized for doing so by one of the world's
most prominent pharmaceutical companies, for two consecutive years, is a
Covance's clinical pharmacology service offering evaluates the safety and
efficacy of potential new drugs in humans, including the conduct of
first-in-human trials. Covance has pioneered many of the specialized services
in its diversified portfolio of drug development services and that uniquely
positions the company as a valued partner in helping to progress compounds
from preclinical to proof-of-concept studies.
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.7 billion, global operations in 25 countries, and
more than 9,800 employees worldwide. Information on Covance's products and
services, recent press releases, and SEC filings can be obtained through its
website at www.covance.com.